DeFi Study Establishes Role of Nirogacestat in Desmoid Tumors
During a live event, Richard F. Riedel, MD, discussed key efficacy and safety outcomes from the phase 3 DeFi trial in patients with progressing desmoid tumors.
0
Comments
0 commentsThere are no comments yet. Be the first to comment!
Discussions automatically close after 96 hours
It's no longer possible to comment on this discussion.